These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36214955)

  • 1. The effect of sodium iodide symporter protein on ablation success in patients with differentiated thyroid cancer.
    Mutevelızade G; Kocer NE; Reyhan M
    Ann Nucl Med; 2022 Dec; 36(12):1050-1058. PubMed ID: 36214955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between expression of the sodium/iodide symporter and 131I uptake in recurrent lesions of differentiated thyroid carcinoma.
    Min JJ; Chung JK; Lee YJ; Jeong JM; Lee DS; Jang JJ; Lee MC; Cho BY
    Eur J Nucl Med; 2001 May; 28(5):639-45. PubMed ID: 11383871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients.
    Yildirim-Poyraz N; Yazgan A; Ozdemir E; Gozalan A; Keskin M; Ersoy R; Turkolmez S; Cakir B
    Ann Nucl Med; 2014 Aug; 28(7):623-31. PubMed ID: 24823701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of Na+/I- symporter in thyroid cancers in an iodine-deficient population: an immunohistochemical study.
    Mishra A; Pal L; Mishra SK
    World J Surg; 2007 Sep; 31(9):1737-1742. PubMed ID: 17653791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake.
    Castro MR; Bergert ER; Goellner JR; Hay ID; Morris JC
    J Clin Endocrinol Metab; 2001 Nov; 86(11):5627-32. PubMed ID: 11701745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism.
    Filetti S; Bidart JM; Arturi F; Caillou B; Russo D; Schlumberger M
    Eur J Endocrinol; 1999 Nov; 141(5):443-57. PubMed ID: 10576759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies.
    Liu YY; van der Pluijm G; Karperien M; Stokkel MP; Pereira AM; Morreau J; Kievit J; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):617-24. PubMed ID: 16712662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of sodium/iodide symporter (NIS) for thyroid cancer management.
    Carvalho DP; Ferreira AC
    Arq Bras Endocrinol Metabol; 2007 Jul; 51(5):672-82. PubMed ID: 17891230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of regulating NIS transport to the cell membrane and redifferentiation therapy in thyroid cancer.
    Cai X; Wang R; Tan J; Meng Z; Li N
    Clin Transl Oncol; 2021 Dec; 23(12):2403-2414. PubMed ID: 34100218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms of radioactive iodine refractoriness in differentiated thyroid cancer: Impaired sodium iodide symporter (NIS) expression owing to altered signaling pathway activity and intracellular localization of NIS.
    Oh JM; Ahn BC
    Theranostics; 2021; 11(13):6251-6277. PubMed ID: 33995657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reintroducing the Sodium-Iodide Symporter to Anaplastic Thyroid Carcinoma.
    Schmohl KA; Dolp P; Schug C; Knoop K; Klutz K; Schwenk N; Bartenstein P; Nelson PJ; Ogris M; Wagner E; Spitzweg C
    Thyroid; 2017 Dec; 27(12):1534-1543. PubMed ID: 29032724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolomics reveals the implication of acetoacetate and ketogenic diet therapy in radioiodine-refractory differentiated thyroid carcinoma.
    Wang J; Xu Q; Xuan Z; Mao Y; Tang X; Yang K; Song F; Zhu X
    Oncologist; 2024 Sep; 29(9):e1120-e1131. PubMed ID: 38760956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Combination Therapy with Lenvatinib and Radioactive Iodine in Thyroid Cancer Preclinical Model.
    Suzuki K; Iwai H; Utsunomiya K; Kono Y; Watabe T; Kobayashi Y; Bui DV; Sawada S; Yun Y; Mitani A; Fukui K; Sakai H; Chu HH; Linh NM; Tanigawa N; Kanda A
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rat sodium iodide symporter allows using lower dose of 131I for cancer therapy.
    Mitrofanova E; Unfer R; Vahanian N; Link C
    Gene Ther; 2006 Jul; 13(13):1052-6. PubMed ID: 16525480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-translational Regulation of Radioactive Iodine Therapy Response in Papillary Thyroid Carcinoma.
    Amit M; Na'ara S; Francis D; Matanis W; Zolotov S; Eisenhaber B; Eisenhaber F; Weiler Sagie M; Malkin L; Billan S; Charas T; Gil Z
    J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 30053080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inverse Agonist of Estrogen-Related Receptor γ Enhances Sodium Iodide Symporter Function Through Mitogen-Activated Protein Kinase Signaling in Anaplastic Thyroid Cancer Cells.
    Singh TD; Jeong SY; Lee SW; Ha JH; Lee IK; Kim SH; Kim J; Cho SJ; Ahn BC; Lee J; Jeon YH
    J Nucl Med; 2015 Nov; 56(11):1690-6. PubMed ID: 26338896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Tyrosine Kinase Inhibitor Can Augment Radioactive Iodine Uptake Through Endogenous Sodium/Iodide Symporter Expression in Anaplastic Thyroid Cancer.
    Oh JM; Baek SH; Gangadaran P; Hong CM; Rajendran RL; Lee HW; Zhu L; Gopal A; Kalimuthu S; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2020 Apr; 30(4):501-518. PubMed ID: 31928162
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of miR-139-5p in radioiodine-resistant thyroid cancer.
    Pecce V; Sponziello M; Verrienti A; Grani G; Abballe L; Bini S; Annunziata S; Perotti G; Salvatori M; Zagaria L; Maggisano V; Russo D; Filetti S; Durante C
    J Endocrinol Invest; 2023 Oct; 46(10):2079-2093. PubMed ID: 36933170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of microRNA-875-5p promotes radioiodine uptake in poorly differentiated thyroid carcinoma cells by upregulating sodium-iodide symporter.
    Tang Y; Meng X; Yu X; Shang H; Chen S; Liao L; Dong J
    J Endocrinol Invest; 2020 Apr; 43(4):439-450. PubMed ID: 31612419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sodium-iodide symporter (NIS) gene expression in lymph-node metastases of papillary thyroid carcinomas.
    Arturi F; Russo D; Giuffrida D; Schlumberger M; Filetti S
    Eur J Endocrinol; 2000 Nov; 143(5):623-7. PubMed ID: 11078986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.